Literature DB >> 27480318

Nanomedicines: From Bench to Bedside and Beyond.

Henry Havel1, Gregory Finch2, Pamela Strode3, Marc Wolfgang3, Stephen Zale4, Iulian Bobe5, Hagop Youssoufian4, Matthew Peterson6, Maggie Liu7.   

Abstract

Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements-only together can they realize the full potential of nanomedicines for patients.

Entities:  

Keywords:  ADME; CMC; PK/PD; academic-industrial collaboration; biodistribution; oncology; preclinical; quality by design; targeted delivery; toxicology

Mesh：

Substances：

Year:  2016        PMID： 27480318     DOI： 10.1208/s12248-016-9961-7

Source DB:  PubMed          Journal:  AAPS J        ISSN： 1550-7416            Impact factor:   4.009


  20 in total

Review 1.  Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

Authors:  Daryl C Drummond; Charles O Noble; Mark E Hayes; John W Park; Dmitri B Kirpotin
Journal:  J Pharm Sci       Date:  2008-11       Impact factor: 3.534

2.  Nanotechnology.

Authors:  Robert Langer; Ralph Weissleder
Journal:  JAMA       Date:  2015-01-13       Impact factor: 56.272

3.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

Authors:  K J Harrington; S Mohammadtaghi; P S Uster; D Glass; A M Peters; R G Vile; J S Stewart
Journal:  Clin Cancer Res       Date:  2001-02       Impact factor: 12.531

4.  Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization".

Authors:  Gregory Finch; Henry Havel; Mostafa Analoui; Randall W Barton; Anil R Diwan; Meliessa Hennessy; Vijayapal Reddy; Nakissa Sadrieh; Lawrence Tamarkin; Marc Wolfgang; Benjamin Yerxa; Banu Zolnik; Man Liu
Journal:  AAPS J       Date:  2014-05-13       Impact factor: 4.009

5.  A review of study designs and outcomes of phase I clinical studies of nanoparticle agents compared with small-molecule anticancer agents.

Authors:  Whitney P Caron; Katherine P Morgan; Beth A Zamboni; William C Zamboni
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

6.  Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

Authors:  Alex Sparreboom; Charity D Scripture; Vuong Trieu; Paul J Williams; Tapas De; Andrew Yang; Bridget Beals; William D Figg; Michael Hawkins; Neil Desai
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

7.  Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Authors:  Jeffrey Hrkach; Daniel Von Hoff; Mir Mukkaram Ali; Elizaveta Andrianova; Jason Auer; Tarikh Campbell; David De Witt; Michael Figa; Maria Figueiredo; Allen Horhota; Susan Low; Kevin McDonnell; Erick Peeke; Beadle Retnarajan; Abhimanyu Sabnis; Edward Schnipper; Jeffrey J Song; Young Ho Song; Jason Summa; Douglas Tompsett; Greg Troiano; Tina Van Geen Hoven; Jim Wright; Patricia LoRusso; Philip W Kantoff; Neil H Bander; Christopher Sweeney; Omid C Farokhzad; Robert Langer; Stephen Zale
Journal:  Sci Transl Med       Date:  2012-04-04       Impact factor: 17.956

Review 8.  Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Authors:  Alberto Gabizon; Hilary Shmeeda; Yechezkel Barenholz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog.

Authors:  E Masini; J Planchenault; F Pezziardi; P Gautier; J P Gagnol
Journal:  Agents Actions       Date:  1985-09

10.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.

Authors:  J I Johnson; S Decker; D Zaharevitz; L V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; M Christian; S Arbuck; M Hollingshead; E A Sausville
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640
View more
  27 in total

1.  The role of hydrophobic modification on hyaluronic acid dynamics and self-assembly.

Authors:  William M Payne; Denis Svechkarev; Alexander Kyrychenko; Aaron M Mohs
Journal:  Carbohydr Polym       Date:  2017-11-08       Impact factor: 9.381

Review 2.  A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products.

Authors:  Greg Troiano; Jim Nolan; Donald Parsons; Christina Van Geen Hoven; Stephen Zale
Journal:  AAPS J       Date:  2016-09-08       Impact factor: 4.009

3.  Progress in Nanomedicine: Approved and Investigational Nanodrugs.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-12

Review 4.  Careers in nanomedicine and drug delivery.

Authors:  Elizabeth Nance
Journal:  Adv Drug Deliv Rev       Date:  2019-06-28       Impact factor: 15.470

Review 5.  Nanomedicine based approaches for combating viral infections.

Authors:  Saurabh Shah; Mahavir Bhupal Chougule; Arun K Kotha; Rama Kashikar; Chandraiah Godugu; Rajeev Singh Raghuvanshi; Shashi Bala Singh; Saurabh Srivastava
Journal:  J Control Release       Date:  2021-08-08       Impact factor: 11.467

6.  Future Treatment of Neuropathic Pain in Spinal Cord Injury: The Challenges of Nanomedicine, Supplements or Opportunities?

Authors:  Giuseppe Forte; Valentina Giuffrida; Angelica Scuderi; Mariella Pazzaglia
Journal:  Biomedicines       Date:  2022-06-10

Review 7.  Nanomedicine-Based Strategies for Diabetes: Diagnostics, Monitoring, and Treatment.

Authors:  Luke R Lemmerman; Devleena Das; Natalia Higuita-Castro; Raghavendra G Mirmira; Daniel Gallego-Perez
Journal:  Trends Endocrinol Metab       Date:  2020-03-04       Impact factor: 12.015

Review 8.  Graphene and other 2D materials: a multidisciplinary analysis to uncover the hidden potential as cancer theranostics.

Authors:  Laura Fusco; Arianna Gazzi; Guotao Peng; Yuyoung Shin; Sandra Vranic; Davide Bedognetti; Flavia Vitale; Acelya Yilmazer; Xinliang Feng; Bengt Fadeel; Cinzia Casiraghi; Lucia Gemma Delogu
Journal:  Theranostics       Date:  2020-04-07       Impact factor: 11.556

9.  Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer.

Authors:  Pallabita Chowdhury; Prashanth K B Nagesh; Sheema Khan; Bilal B Hafeez; Subhash C Chauhan; Meena Jaggi; Murali M Yallapu
Journal:  Acta Pharm Sin B       Date:  2017-12-10       Impact factor: 11.413

10.  Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.

Authors:  Neeta Bala Tannan; Mandana T Manzari; Laurie Herviou; Mariana Da Silva Ferreira; Connor Hagen; Hiroto Kiguchi; Katia Manova-Todorova; Venkatraman Seshan; Elisa de Stanchina; Daniel A Heller; Anas Younes
Journal:  Blood       Date:  2021-04-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.